Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?

Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer is an aggressive phenotype with a poor prognosis, and can easily metastasize and recur. Currently, chemotherapy plus HER2-targeted therapy is the standard systemic treatment for most of these patients. Given that neoadjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Juan, Kong, Rong, Tian, Shen, Li, Hao, Wu, Kainan, Kong, Lingquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955160/
https://www.ncbi.nlm.nih.gov/pubmed/31949390
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.06.04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955160/
https://www.ncbi.nlm.nih.gov/pubmed/31949390
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.06.04

Ejemplares similares